Response by Kosiborod et al to Letters Regarding Article, "Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors)"

Affiliations

• ¹ Saint Luke's Mid America Heart Institute and University of Missouri-Kansas City (M.K.).
• ² University of North Carolina, Chapel Hill (M.A.C.).
• ³ Georgetown University Medical Center, Washington, DC (A.Z.F.).
• ⁴ University of Liverpool, United Kingdom (J.P.W.).
• ⁵ University of Leicester, United Kingdom (K.K.).
• ⁶ University of Ulm, Germany (R.W.H.).
• ⁷ Karolinska Institutet, Stockholm, Sweden (A.N., N.H.).
• ⁸ University of Oslo, Norway (K.I.B.).
• ⁹ Oslo University Hospital, Norway (K.I.B.).
• ¹⁰ Steno Diabetes Center, Copenhagen, Denmark (M.E.J.).
• ¹¹ National Institute of Public Health, Southern Denmark University (M.E.J.).
• ¹² Statisticon AB, Uppsala, Sweden (M.T.).
• ¹³ AstraZeneca, Gaithersburg, MD (N.A.).
• ¹⁴ AstraZeneca, Oslo, Norway (J.B.).
• ¹⁵ AstraZeneca Gothenburg, Sweden (N.H.).
• ¹⁶ AstraZeneca, Cambridge, United Kingdom (P.F.).